Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

307 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immuno-Molecular Targeted Therapy Use and Survival Benefit in Patients with Stage IVB Cervical Carcinoma in Commission on Cancer®-Accredited Facilities in the United States.
Sitler CA, Tian C, Hamilton CA, Richardson MT, Chan JK, Kapp DS, Leath CA 3rd, Casablanca Y, Washington C, Chappell NP, Klopp AH, Shriver CD, Tarney CM, Bateman NW, Conrads TP, Maxwell GL, Phippen NT, Darcy KM. Sitler CA, et al. Among authors: washington c. Cancers (Basel). 2024 Mar 6;16(5):1071. doi: 10.3390/cancers16051071. Cancers (Basel). 2024. PMID: 38473428 Free PMC article.
Olaparib in the treatment of ovarian cancer.
Washington CR, Richardson DL, Moore KN. Washington CR, et al. Future Oncol. 2019 Oct;15(30):3435-3449. doi: 10.2217/fon-2019-0271. Epub 2019 Sep 3. Future Oncol. 2019. PMID: 31478762 Review.
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K, Castellano T, Washington C, Ting J, Surinach A, Kirshner C, Chhatwal J, Ayer T, Moore K. Sonawane K, et al. Among authors: washington c. Gynecol Oncol Rep. 2022 Nov 5;44(Suppl 1):101101. doi: 10.1016/j.gore.2022.101101. eCollection 2022 Dec. Gynecol Oncol Rep. 2022. PMID: 36506039 Free PMC article.
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K, Castellano T, Washington C, Ting J, Surinach A, Kirshner C, Chhatwal J, Ayer T, Moore K. Sonawane K, et al. Among authors: washington c. Gynecol Oncol Rep. 2022 Dec 13;44:101121. doi: 10.1016/j.gore.2022.101121. eCollection 2022 Dec. Gynecol Oncol Rep. 2022. PMID: 36589508 Free PMC article.
TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL, Corr BR, Ayoola-Adeola M, Wright JD, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono AAH, Powell K, Herzog TJ, Salani R, Alvarez Secord A. Whelan K, et al. Among authors: washington c. Gynecol Oncol. 2023 Nov;178:44-53. doi: 10.1016/j.ygyno.2023.09.009. Epub 2023 Sep 23. Gynecol Oncol. 2023. PMID: 37748270
Advances in antibody-drug conjugates for gynecologic malignancies.
Tymon-Rosario J, Gorman M, Richardson DL, Washington C, Santin AD. Tymon-Rosario J, et al. Among authors: washington c. Curr Opin Obstet Gynecol. 2023 Feb 1;35(1):6-14. doi: 10.1097/GCO.0000000000000838. Epub 2022 Dec 8. Curr Opin Obstet Gynecol. 2023. PMID: 36484278 Review.
Updates in the Use of Targeted Therapies for Gynecologic Cancers.
Cantillo E, Blanc-Durand F, Leary A, Slomovitz BM, Fuh K, Washington C. Cantillo E, et al. Among authors: washington c. Am Soc Clin Oncol Educ Book. 2024 Jun;44(3):e438582. doi: 10.1200/EDBK_438582. Am Soc Clin Oncol Educ Book. 2024. PMID: 38788185 Free article. Review.
307 results